Active Biotech AB Interim report January - September 2012

Active Biotech AB Interim report January - September 2012 
LUND, SWEDEN -- (Marketwire) -- 11/09/12 --  
- Laquinimod - Teva to initiate a new Phase III study in the US at
year-end 
- milestone payment of USD 5 M received
following a submitted
application for regulatory approval in Europe   
- Crohn's Phase II data presented at the UEGW
conference 
- TASQ        - biomarker data presented at the ESMO conference       
- Ipsen to initiate two new clinical Phase II studies:
maintenance therapy for prostate cancer and a study of other types of
cancer 
- ANYARA   - Phase III study results to be presented Q1 2013 
- 57-57        - clinical trial of systemic sclerosis/scleroderma is
in progress 
- ISI            - project proceeding as planned 
- Net sales:  SEK 136.4 M (231.3) 
- Operating loss: SEK 168.7 M (loss 6.2) 
- Loss after tax: SEK 175.1 M (loss: 1.3) 
- Loss per share for the period: SEK 2.54 (loss: 0.02) 
This report is also available at www.activebiotech.com 
Active Biotech AB Interim report January - September 2012:
http://hugin.info/1002/R/1656396/535516.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Active Biotech via Thomson Reuters ONE 
[HUG#1656396] 
For further information, please contact: 
Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95 
Hans Kolam
CFO
Tel: +46 (0)46 19 20 44 
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
 
 
Press spacebar to pause and continue. Press esc to stop.